# Tyra Biosciences (TYRA) Stock Analysis: A Biotech with 92% Upside Potential

- Link: https://www.directorstalkinterviews.com/tyra-biosciences-tyra-stock-analysis-a-biotech-with-92-upside-potential/4121259610
- Published: 2026-08-07T10:20:04+01:00
- Author: Madison Wilson

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company, has
captured investor attention with its promising pipeline and remarkable upside potential.
With an impressive projected upside of 92.14% based on the average analyst target
price of $51.80, Tyra Biosciences stands out in the healthcare sector, particularly
within the biotechnology industry.

Headquartered in Carlsbad, California, Tyra Biosciences was founded in 2018 and 
is focused on developing precision medicines for fibroblast growth factor receptor(
FGFR) biology. The company’s innovative SNÅP platform leverages iterative molecular
snapshots to design drugs that target genetic alterations, aiming to treat conditions
like metastatic urothelial carcinoma and various solid tumors.

Currently trading at $26.96, the company’s stock has shown a price change of 1.25(
0.05%) recently. Its 52-week range indicates a volatile journey, oscillating between
$10.10 and $39.61, reflecting the inherent risks and potential rewards associated
with biotech investments.

Despite the absence of traditional valuation metrics like P/E and PEG ratios, Tyra
Biosciences’ financial outlook is buoyed by strong analyst support. With 14 buy 
ratings against just one hold and no sell ratings, the sentiment is overwhelmingly
positive. Analysts have set a target price range between $42.00 and $59.62, underscoring
the stock’s growth potential.

However, it’s important to consider the challenges inherent in a biotech investment
at this stage. The company reported a negative EPS of -2.50 and a return on equity
of -45.31%, indicating that profitability is not yet within reach. Moreover, Tyra
Biosciences is currently operating with negative free cash flow of -$68.3 million,
which may necessitate further capital raising to fund its ambitious research and
development programs.

Technically, the stock’s 50-day moving average of $30.32 and 200-day moving average
of $29.17 suggest that it is trading below these key levels, potentially offering
a buying opportunity for long-term investors. Nevertheless, the Relative Strength
Index (RSI) of 72.42 indicates overbought conditions, which may warrant caution 
for short-term traders.

While Tyra Biosciences does not offer a dividend, a common characteristic for companies
in the clinical-stage biotech space, its zero payout ratio highlights a focus on
reinvesting earnings into product development rather than shareholder returns.

For investors eyeing the biotechnology sector, Tyra Biosciences presents an intriguing
proposition with its groundbreaking approach to precision medicine and expansive
product pipeline. The company’s lead candidates, including FGFR3 for metastatic 
urothelial carcinoma and TYRA-300 for skeletal conditions, are at the forefront 
of its growth strategy.

In the speculative yet potentially rewarding world of biotech, Tyra Biosciences 
offers a compelling case for investors willing to embrace the risks associated with
early-stage drug development. With significant upside potential and strong analyst
endorsements, TYRA could be a standout performer in a well-diversified investment
portfolio.

Share on:
